

CONTENTS

ABSTRACT	vi
LIST OF FIGURES	viii
LIST OF TABLES	ix
ACKNOWLEDGEMENT	x
CHAPTER 1: INTRODUCTION	1
CHAPTER 2: LITERATURE REVIEW	7
2.1 Epidemiology	
A) Global scenario	7
B) Malaysian scenario	8
2.2 Etiological factors	10
2.2.1 Risk habits	
A) Tobacco	10
B) Alcohol	11
C) Quid Chewing	12
D) The Trio – tobacco, alcohol and quid	14
2.2.2 Infections	14
A) Viruses	14
B) Bacteria	16
C) Fungal	17

2.2.3 Genetic Predispositions	17
2.2.4 Mouthrinse	18
2.2.5 Dental Factors	19
2.2.6 Diet and nutrition	19
2.2.7 Immunosuppression	20
2.2.8 Others	21
2.3 Oral squamous cell carcinoma – diagnosis, prognosis and survival	21
2.4 Oral carcinogenesis – cellular and molecular basis	27
2.4.1 Cellular basis of oral carcinogenesis	27
2.4.2 Molecular event of oral carcinogenesis	31
2.4.2.1 Cell cycle control	31
2.4.2.2 Measuring proliferative rate	32
A) Ki-67	33
B) Ki-67 – proliferative cum prognostic marker	34
2.4.2.3 Tumour suppressor genes (TSGs)	36
A) Molecule of the year 1993, the p53.	37
B) p53, the discovery	37
C) p53 protein	39
D) p53 network	39
E) p53 – a prognostic marker?	41
2.4.2.4 Murine Minute Double 2, the MDM-2 gene	44
A) Expression of MDM- protein in cancers	45
2.4.2.5 Apoptosis	46
2.4.2.6 Bcl-2 protein family	47
A) Bcl-2	47

B) Bcl-2, mechanism of action	48
C) Expression of Bcl-2 in OSCC	49
CHAPTER 3: MATERIALS AND METHODS	50
3.1 Samples selection	50
A) Inclusion criteria	50
B) Exclusion criteria	50
3.2 Data collection	51
3.3 Laboratory procedures	56
3.3.1 Specimens processing	56
3.3.2 Staining procedures	56
a) Haematoxylin and Eosin (H&E) staining	56
b) Immunohistochemistry staining	56
i) Ki-67	56
ii) p53	58
iii) Bcl-2	59
iv) MDM-2	59
3.5 Histopathological and Immunohistochemistry Evaluation	60
A) Broders' Classification	60
B) Pattern of invasion	60
C) Immunohistochemical evaluation	60
3.6 Statistical analysis	62
CHAPTER 4: RESULTS	63

4.1 Demographic characteristics	63
4.2 Clinicopathological features	
A) TNM Staging with T and N status	66
B) Broders Classification	68
C) Pattern of Invasion	68
4.3 Immunohistochemical expression	70
A) Ki-67 Labeling Index (LI)	70
B) p53 expression	70
C) MDM-2 expression	71
D) Bcl-2 expression	71
4.4 Relationship between Ki-67 status or Labeling Index (LI) and overexpression of p53, MDM-2 and Bcl-2.	73
4.5 Relationship between Ki-67 status or Labeling Index (LI) and overexpression of p53/Bcl-2, p53/MDM-2 and MDM-2/Bcl-2	75
4.6 Relationship of demographic and clinicopathological parameters with Ki-67 status, overexpression of p53, MDM-2 and Bcl-2	76
4.7 Relationship of demographic and clinicopathological parameters with combined expression of the markers.	76
CHAPTER 5: DISCUSSION	84
5.1 Sample size	84
5.2 Age	84
5.3 Gender and Ethnicity	85
5.4 Sites	85

5.5 TNM Staging	86
5.6 Broders' classification & pattern of invasion	86
5.7 Evaluation of expression of Ki-67, p53, MDM-2 and Bcl-2 at the tumour invasive front and relationship to other clinicopathological parameters	87
A) Ki-67 Labelling Index	87
B) Expression of p53	89
C) Expression of MDM-2	92
D) Expression of Bcl-2	94
5.8 Evaluation of coexpression Ki-67, MDM-2, p53 and Bcl-2 at the tumour invasive front in relation to clinicopathological parameters.	96
A) MDM-2 and p53 expression	96
B) p53 expression, Ki-67 LI and Bcl-2 expression	97
CHAPTER 6: CONCLUSION & RECOMMENDATIONS	100
CHAPTER 7: REFERENCES	102
APPENDIX	130